Abstract
The current treatment regimens for uncomplicated malaria comprise an artemisinin in combination with another drug (ACT). However, the recent emergence of resistance to ACTs in South East Asia dramatically emphasizes the need for new artemisinins. The current artemisinins have been in use since the late 1970s and have relatively poor thermal, chemical and metabolic stabilities - all are metabolized or hydrolyzed in vivo to dihydroartemisinin (DHA) that itself undergoes facile decomposition in vivo. The current artemisinins possess neurotoxicity as demonstrated in animal models, an issue that mandates increased vigilance in view of trends to use of protracted treatment regimens involving sequential administration of different ACTs against the resistant disease. As artemisinins induce the most rapid reduction in parasitaemia of any drug, common sense dictates that any new artemisinin derivative, selected on the bases of more robust chemical and thermal stability, metabolic stability with respect to the generation of DHA in vivo, and relatively benign neurotoxicity should be used in any new ACT whose components are rationally chosen in order to counter resistant malaria and inhibit transmission. 11-Azaartemisinin and its N-substituted derivatives attract because of overall ease of preparation from artemisinin. Some derivatives also possess notable thermal stabilities and although metabolic pathways of the derivatives are as yet unknown, none can provide DHA. The azaartemisinins synthesized over the past 20 years are critically discussed on the basis of their synthetic accessibility and biological activities with the view to assessing suitability to serve as new artemisinin derivatives for treatment of malaria.
Keywords: Artemisinin, azaartemisinin, dihydroartemisinin, malaria, metabolism, resistance, stability.
Current Medicinal Chemistry
Title:The Case for Development of 11-Aza-artemisinins for Malaria
Volume: 22 Issue: 31
Author(s): Rozanne Harmse, Ho Ning Wong, Frans Smit, Richard K. Haynes and David D. N'Da
Affiliation:
Keywords: Artemisinin, azaartemisinin, dihydroartemisinin, malaria, metabolism, resistance, stability.
Abstract: The current treatment regimens for uncomplicated malaria comprise an artemisinin in combination with another drug (ACT). However, the recent emergence of resistance to ACTs in South East Asia dramatically emphasizes the need for new artemisinins. The current artemisinins have been in use since the late 1970s and have relatively poor thermal, chemical and metabolic stabilities - all are metabolized or hydrolyzed in vivo to dihydroartemisinin (DHA) that itself undergoes facile decomposition in vivo. The current artemisinins possess neurotoxicity as demonstrated in animal models, an issue that mandates increased vigilance in view of trends to use of protracted treatment regimens involving sequential administration of different ACTs against the resistant disease. As artemisinins induce the most rapid reduction in parasitaemia of any drug, common sense dictates that any new artemisinin derivative, selected on the bases of more robust chemical and thermal stability, metabolic stability with respect to the generation of DHA in vivo, and relatively benign neurotoxicity should be used in any new ACT whose components are rationally chosen in order to counter resistant malaria and inhibit transmission. 11-Azaartemisinin and its N-substituted derivatives attract because of overall ease of preparation from artemisinin. Some derivatives also possess notable thermal stabilities and although metabolic pathways of the derivatives are as yet unknown, none can provide DHA. The azaartemisinins synthesized over the past 20 years are critically discussed on the basis of their synthetic accessibility and biological activities with the view to assessing suitability to serve as new artemisinin derivatives for treatment of malaria.
Export Options
About this article
Cite this article as:
Harmse Rozanne, Wong Ning Ho, Smit Frans, Haynes K. Richard and N'Da D. David, The Case for Development of 11-Aza-artemisinins for Malaria, Current Medicinal Chemistry 2015; 22 (31) . https://dx.doi.org/10.2174/0929867322666150729115752
DOI https://dx.doi.org/10.2174/0929867322666150729115752 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emergence of Ad-Mediated Combination Therapy Against Cancer: What to Expect?
Current Cancer Drug Targets Medicinal Properties of the Jamaican Pepper Plant Pimenta dioica and Allspice
Current Drug Targets Applications of Mesoporous Materials as Excipients for Innovative Drug Delivery and Formulation
Current Pharmaceutical Design The Place of Somatostatin Analogs in the Diagnosis and Treatment of the Neuoroendocrine Glands Tumors
Recent Patents on Anti-Cancer Drug Discovery Scyphomedusae of the Mediterranean: State of the Art and Future Perspectives
Central Nervous System Agents in Medicinal Chemistry The Role of Protonation States in Ligand-Receptor Recognition and Binding
Current Pharmaceutical Design Exosomal microRNAs as Potentially Useful Tools in Cancer Biomarker Discovery
Recent Patents on Biomarkers Vitamin C: Basic Metabolism and Its Function as an Index of Oxidative Stress
Current Medicinal Chemistry Novel Classes of Dimer Antitumour Drug Candidates
Current Pharmaceutical Design LPTS: A Novel Tumor Suppressor Gene and a Promising Drug Target for Cancer Intervention
Recent Patents on Anti-Cancer Drug Discovery Giardiasis in the Post Genomic Era: Treatment, Drug Resistance and Novel Therapeutic Perspectives
Infectious Disorders - Drug Targets Combating Malaria with Plant Molecules: A Brief Update
Current Medicinal Chemistry Extrinsic Factors Promoting Insulin Producing Cell-Differentiation and Insulin Expression Enhancement-Hope for Diabetics.
Current Stem Cell Research & Therapy Prolonged Release of Anti-Retroviral Efavirenz From System Using ZIF-8 as Carrier
Current HIV Research Mechanisms of Cytotoxicity of Anticancer Titanocenes
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Options in Prevention and Treatment of Aspartoacylase Gene Mutation Resulting Abnormalities in Canavan Disease
Current Pharmacogenomics Cellular and Subcellular Imaging in Live Mice Using Fluorescent Proteins
Current Pharmaceutical Biotechnology Pharmacogenetics of Irinotecan
Current Medicinal Chemistry - Anti-Cancer Agents Intestinal Epithelial Barrier Dysfunction in Disease and Possible Therapeutical Interventions
Current Medicinal Chemistry The In-Situ One-Step Synthesis of a PDC Macromolecular Pro-Drug and the Fabrication of a Novel Core-Shell Micell
Current Pharmaceutical Design